HEPATITIS C
Acute and Chronic
(Not Perinatal)

REPORTING INFORMATION
• **Class B:** Report the case, suspected case and/or a positive laboratory result to the local public health department where the patient resides by the close of the next business day. If patient residence is unknown, report to the local public health department in which the reporting health care provider or laboratory is located.

• Health care providers and laboratories report using the following form(s) and/or mechanisms: *Viral Hepatitis Case Report form*, *Ohio Confidential Reportable Disease form* (HEA 3334, rev. 5/2014), *Positive Laboratory Findings for Reportable Disease form* (HEA 3333, rev. 8/2005), *Ohio Hepatitis C: Case Collection form* (HEA 0201, 9/2018), *Ohio Disease Reporting System (ODRS)*, electronic laboratory reporting, or telephone.

• Local public health departments report the case, suspected case and/or a positive laboratory result to the Ohio Department of Health (ODH) via ODRS by the end of the next business day. Information should not be sent to ODH, unless requested.

• Key fields for ODRS reporting include:
  o **Patient Demographics**
    ▪ First and last name
    ▪ Date of birth or age (including age type),
    ▪ Sex at birth
    ▪ Race and Ethnicity
    ▪ Pregnancy status
  o **Laboratory Information**
    ▪ Test name
    ▪ Result (qualitative)
    ▪ Numeric results (quantitative)
    ▪ Reference range for numeric test results
    ▪ Do not enter Organism if the test is anti-HCV, HCV RNA, or ALT, as these tests do not identify the organism.
  o **Clinical Information**
    ▪ Was patient jaundiced?
    ▪ Jaundice onset date
    ▪ Elevated alanine aminotransferase (ALT) (enter in Laboratory Information)
    ▪ Total Bilirubin (enter in Laboratory Information)
  o **Epidemiology Information – pay special attention to questions related to healthcare associated transmission (e.g. transfusion, dental work), drug use, incarceration, tattooing, and piercing.**

AGENT
Hepatitis C virus (HCV) is classified in the genus *Hepacivirus* in the *Flaviviridae family*. Hepatitis C virus is a single-stranded RNA virus, 55-65 nm in diameter. There are seven distinct genotypes and more than 67 subtypes of the HCV virus.

TEST NAME ABBREVIATIONS

<table>
<thead>
<tr>
<th>Name</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alanine aminotransferase</td>
<td>ALT (SGPT)</td>
</tr>
<tr>
<td>Antibody to hepatitis C virus</td>
<td>Anti-HCV</td>
</tr>
<tr>
<td>Hepatitis C virus ribonucleic acid</td>
<td>HCV RNA</td>
</tr>
<tr>
<td>Hepatitis C virus nucleic acid</td>
<td>HCV NAT</td>
</tr>
</tbody>
</table>
CASE DEFINITION

Clinical Criteria for Diagnosis
Cases under the age of 36 months should be classified under the Perinatal HCV Position Statement (17-ID-08) unless the exposure mode is not perinatal (e.g., healthcare acquired).

Acute
A new acute case is an incident case that is over the age of 36 months and has not previously been reported meeting case criteria for chronic hepatitis C or for whom there is laboratory evidence of re-infection AND a) jaundice OR b) a peak elevated serum alanine aminotransferase (ALT) level greater than 200 IU/L OR c) peak elevated Total Bilirubin levels ≥3.0 mg/dL during the period of acute illness. Symptoms are not required for acute cases.

Chronic
No available evidence of clinical or relevant laboratory information indicative of acute infection. Most hepatitis C virus-infected persons are asymptomatic; however, many have chronic liver disease, which can range from mild to severe.

Laboratory Criteria for Diagnosis
- A positive test for antibodies to hepatitis C virus (anti-HCV) positive, OR
- Hepatitis C virus detection test:
  - Nucleic acid test (NAT) for HCV RNA positive (including qualitative, quantitative or genotypetesting)
  - A positive test indicating presence of hepatitis C viral antigen(s) (HCV antigen – when and if a test is approved by FDA and available)

Case Classification

Acute, Confirmed
- A case that meets clinical criteria and has a positive hepatitis C virus detection test (NAT or HCV antigen) in the absence of a more likely diagnosis, OR
- A documented negative HCV antibody OR negative hepatitis C virus detection test (in someone without a prior diagnosis of HCV infection) followed within 12 months by a positive hepatitis C virus detection test (HCV RNA test conversion)

Acute, Probable
- A case that meets clinical criteria and has a positive anti-HCV antibody test, but has no reports of a positive HCV NAT for HCV RNA or HCV antigen in the absence of a more likely diagnosis, AND
- Does not have test conversion within 12 months or has no report of test conversion

Chronic, Confirmed
- A case that does not meet clinical criteria or has no report of clinical criteria, AND
- Does not have test conversion within 12 months or has no report of test conversion, AND
- Has a positive HCV NAT or HCV antigen test

Chronic, Probable
- A case that does not meet clinical criteria or has no report of clinical criteria, AND
- Does not have a test conversion within 12 months or has no report of test conversion, AND
- Has a positive anti-HCV antibody test, but no report of a positive HCV NAT or positive HCV antigen test
Criteria to Distinguish a New Case of this Disease from Reports or Notifications Which Should not be Enumerated as a New Case for Surveillance

A new case is an incident case (new acute or newly diagnosed chronic) that has not previously been reported meeting case criteria for hepatitis C. A new probable acute case may be reclassified as confirmed acute case if a positive NAT for HCV RNA or a positive HCV antigen(s) test is reported within the same reporting year. A confirmed acute case may be classified as a confirmed chronic case if a positive NAT for HCV RNA or a positive HCV antigen is reported one year or longer after acute case onset. A confirmed acute case may not be reported as a probable chronic case (i.e., HCV antibody positive, but with an unknown HCV RNA NAT or antigen status). States and territories may choose to track resolved hepatitis C cases in which spontaneous clearance of infection or sustained viral response to treatment are suspected to have occurred before national notification or are known to have occurred after national notification as a confirmed or probable case to CDC.

For Probable Acute HCV

If the initial tests (ordered the same day) include both a positive anti-HCV and a negative HCV RNA, the case will be classified as “Not a Case” since the person does not have current infection. If the person has a positive anti-HCV, followed by a negative HCV RNA that was collected more than 30 days after the collection date of a positive anti-HCV along with the presence of jaundice, ALT >200 IU/L, or total bilirubin ≥3.0 mg/dL, the cases will remain probable acute.

For Probable Chronic HCV

If a positive anti-HCV is followed by a negative HCV RNA within six months, the case will be classified as “Not a Case.” If a positive anti-HCV is followed by a negative HCV RNA after six months, the case will remain a Probable Chronic case (per guidance from CDC).

EVIDENCE FOR REINFECTION

Evidence for re-infection may include a case of confirmed chronic HCV infection that has at least two sequential negative HCV viral detection tests reported, indicative of treatment initiation and sustained virologic response, followed by a positive HCV viral detection test. Under current treatment recommendations, those two negative tests should be at least three months apart, however, the timing may change as standard of care for HCV treatment evolves. Other evidence of reinfection should be considered, including a report of a new genotype on a case that has previously cleared a different genotype. Jurisdictions are encouraged to ensure that cases of HCV treatment failure are not classified as new cases of HCV infection to the extent that it can be determined. Jurisdictions tracking re-infection should also consider collecting data on prior treatment completion (when relevant and possible to document), treatment failure, change in reported genotype if that applies, and the known time frame for reinfection. If there is evidence of reinfection (two negative HCV viral detection tests ≥3 months apart, followed by a positive HCV viral detection test), then a new chronic case should be created.

SIGNS AND SYMPTOMS

Acute hepatitis C is defined as the first 12 months after an individual is infected with hepatitis C. Acute infection is usually asymptomatic. Symptomatic infection is generally mild, with malaise being the most common manifestation. Fulminant disease is rare. When symptoms do occur, they can include fever, fatigue, dark urine, clay-colored stools, abdominal pain, loss of appetite, nausea, vomiting, joint pain, and jaundice. However, the above-mentioned symptoms are not required to meet the acute case definition. After acute infection, approximately 15% - 25% of persons resolve their infection without sequelae as defined by sustained absence of HCV RNA in serum and normalization of ALT levels.
Chronic hepatitis C is defined as infection with hepatitis C virus that continues beyond the acute phase (or 12 months). Chronic infection develops in 75% - 85% of those infected. Chronic liver disease develops in 60% - 70% of chronically infected persons and is accompanied by persistent or fluctuating ALT levels; the progression of disease is usually slow and without symptoms or physical signs during the first two or more decades after infection. Cirrhosis develops in 5% - 20% of the chronically infected over a period of 20-30 years, and hepatocellular carcinoma develops in 1% - 5%.

A small percentage of persons with chronic HCV infection develop medical conditions due to HCV that are not limited to the liver. Such conditions can include:

- Fatigue
- Diabetes mellitus
- Glomerulonephritis
- Essential mixed cryoglobulinemia
- Porphyria cutanea tarda
- Non-Hodgkin’s lymphoma

**DIAGNOSIS**

Testing for hepatitis C begins with either a rapid or a laboratory-conducted assay for hepatitis C virus antibody in blood.

A nonreactive hepatitis C virus antibody result indicates no hepatitis C virus antibody was detected.

A reactive result indicates one of three things:

- Current hepatitis C infection
- Past hepatitis C infection that has resolved
- False positivity

A reactive result should be followed by a nucleic acid test (NAT) for hepatitis C RNA.

- If hepatitis C RNA is detected, that indicates current hepatitis C infection.
- If hepatitis C RNA is not detected, that indicates either resolved hepatitis C infection or false hepatitis C antibody positivity.

The table below summarizes interpretation of laboratory findings:

<table>
<thead>
<tr>
<th>Laboratory Findings</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-HCV Screening</strong></td>
<td><strong>Anti-HCV Supplemental Test</strong></td>
</tr>
<tr>
<td>Negative</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Positive</td>
<td>Not Done</td>
</tr>
<tr>
<td>Positive</td>
<td>HCV RNA Positive</td>
</tr>
<tr>
<td>Positive</td>
<td>HCV RNA Negative</td>
</tr>
</tbody>
</table>

*If the person tested is suspected of having hepatitis C exposure within the past year, has clinical evidence of hepatitis C, or if there is concern regarding the handling or storage of the test specimen.
EPIDEMIOLOGY

Source
Hepatitis C virus (HCV) is found in human blood and blood products.

Occurrence
Hepatitis C infection is prevalent throughout the world and is the most common chronic bloodborne infection in the United States. Each year since 2013, there has been an increase in new hepatitis C cases in the United States, from 29,700 to 50,300 estimated cases in 2018 with an estimated 2.4 million adults in the United States living with hepatitis C during 2013–2016. Nationally, the peak prevalence is in persons born between approximately 1945 and 1965, the majority of whom were likely infected during the 1970s and 1980s when rates for hepatitis C were the highest. Concurrent with the nation’s opioid crisis, in more recent years, new HCV infections have occurred primarily among young adults, including persons of reproductive age. In 2016, Ohio peak prevalence occurred in persons 20-29 years of age. Individuals that are chronically infected serve as a source of transmission to others and are at risk for chronic liver disease or other hepatitis C-related sequelae.

Mode of Transmission
Hepatitis C is transmitted through exposure to infectious blood or body fluids that contain blood. Currently, the most common mode of transmission in the U.S occurs due to injection drug use, through transfer of infected blood by sharing needles or other drug paraphernalia. Hepatitis C is rarely transmitted by blood transfusion (less than one chance per two million units transfused) or organ transplantation; however, prior to donor screening, both blood transfusion and organ transplantation carried a high risk for transmission of hepatitis C. With recent advancements in the development of direct acting antivirals to treat and effectively cure hepatitis C infections, there has been an increase in the intentional transplantation of HCV viremic donor organs in HCV-negative recipients, thus increasing the number of available organs for transplantation. Healthcare-associated transmission of hepatitis C is possible if infection control techniques or disinfection procedures are inadequate and contaminated equipment is shared among patients. Healthcare, emergency medical and public safety workers who are exposed to blood in the workplace are at risk of being infected with blood borne pathogens, including hepatitis C. Sexual transmission of hepatitis C appears to occur, but the virus is inefficiently spread in this manner. Having a sexually transmitted disease (STD) or HIV, sex with multiple partners, or rough sex appears to increase a person's risk for Hepatitis C. Hepatitis C transmission to non-sexual household contacts, presumably through direct or inapparent percutaneous or permucosal exposure to infectious blood or body fluids containing blood, is uncommon. Approximately six percent of infants born to HCV-infected mothers become infected with the virus. As perinatal transmission of Hepatitis C can occur at the time of birth, there is no prophylaxis available to prevent it. The risk is increased by the presence of maternal HCV viremia at delivery and is two to three times greater if mother is co-infected with HIV. A person may become infected with a different strain of hepatitis C after clearing the initial infection. Prior infection with HCV does not protect against later infection with the same or different genotypes of the virus. This is because persons infected with HCV typically have an ineffective immune response due to changes in the virus during infection. For the same reason, no effective pre- or postexposure prophylaxis (i.e., immune globulin) is available.

Period of Communicability
Communicability lasts from one or more weeks before onset of first symptoms through the acute clinical course of the disease and indefinitely in the chronic stage.

Incubation Period
The incubation period averages six to nine weeks with a range of two to six months. The time from exposure to the development of viremia (the presence of virus in the blood) is one to three weeks.
“At-Risk” Groups
Groups at high-risk of acquiring this infection are:

- Current or former injection drug users, including those who injected only once many years ago
- Recipients of clotting factor concentrates made before 1987, when more advanced methods for manufacturing those products were developed
- Recipients of blood transfusions or solid organ transplants before July 1992, when better testing of blood donors became available
- Chronic hemodialysis patients
- Persons with known exposures to HCV, such as
  - Health care worker after needle sticks involving HCV-positive blood
  - Recipients of blood or organs from a donor who tested HCV-positive
- Persons with HIV infection
- Children born to HCV-positive mothers

PUBLIC HEALTH MANAGEMENT

Case Investigation
Determine through the patient’s physician if the patient is/was acutely ill (symptoms, symptom onset date, has jaundice, an elevated ALT or total bilirubin ≥3.0mg/dL).

Treatment
For information regarding treatment of hepatitis C, please refer to the treatment guidelines at http://www.hcvguidelines.org. The goal of hepatitis C treatment is a sustained virologic response (SVR), which can be considered a cure and is expected to benefit nearly all chronically infected persons. Only those with short life expectancy that cannot be remediated by HCV therapy, liver transplantations, or another directed therapy should not receive treatment. The treatment regimen depends on the HCV genotype. Treatment will reduce liver-related adverse consequences of long-term HCV infection, such as end-stage liver disease, liver cancer, and death. Reduction in HCV transmission will also occur with treatment. New treatment guidelines recommend no treatment of acute HCV. Patients with acute HCV infection should be followed and only considered for treatment if HCV RNA persists after six months.

All persons with chronic hepatitis C should be vaccinated against hepatitis A and B because of the high rate of severe hepatitis in those with chronic liver disease from hepatitis C who become coinfected with one of these infections.

Isolation
Use universal Precautions. Persons diagnosed with hepatitis C should not donate blood, tissue, or semen.

Contacts
Prevention and Control
General control measures against hepatitis B virus infection apply for hepatitis C virus infection as well (see hepatitis B elsewhere in this manual). The value of prophylactic immunoglobulin (IG), however, is not clear. Current data suggest that postexposure prophylaxis with IG is not effective in preventing hepatitis C infection. No assessments have been made of postexposure use of antiviral agents. There is no vaccine available.

Children Born to Mothers with Hepatitis C Infection
See chapter on Perinatal HCV
**Special Information**

Questions about reporting, surveillance, and epidemiology for acute or chronic hepatitis C or requests for data should be directed to the Hepatitis Surveillance Program at: hepatitis@odh.ohio.gov.

Questions about the testing, prevention, and control of acute or chronic hepatitis C should be directed to the Hepatitis Prevention Program at: hepatitis@odh.ohio.gov.

Many excellent fact sheets and other resources are available at the CDC Website: http://www.cdc.gov/hepatitis.
What is hepatitis C?
Hepatitis C is a virus that uses liver cells to reproduce. As the body’s immune system works to defend against this virus, inflammation, injury, and ultimately scarring of the liver may occur. The hepatitis C virus is found in the blood of persons who have this disease. Hepatitis C is spread by contact with the blood of an infected person.

How is hepatitis C diagnosed?
Two blood tests can be done to determine if you have been infected with hepatitis C. Your doctor may order just one or both tests. The following are the types of tests your doctor may order and the purpose for each:

- Anti-HCV (antibody to hepatitis C)
  This test is usually done first. If positive, it should be confirmed with an HCV RNA. A positive anti-HCV in a person who has not been previously reported meets the case definition for probable acute hepatitis C if clinical criteria are present or the case definition for probable chronic hepatitis C if clinical criteria are not present.

- HCV RNA (also referred to as NAT or PCR)
  This test will tell you if you have the virus present in your blood, which indicates that you are currently infected. A positive HCV RNA without clinical criteria meets the case definition for confirmed, chronic hepatitis C, while a positive HCV RNA with clinical criteria meets the case definition for confirmed, acute hepatitis C.

Who should be tested for hepatitis C?
HCV testing is recommended for anyone at increased risk for HCV infection, including:

- Current or former injection drug users, including those who injected only once many years ago
- Everyone born from 1945 through 1965
- Recipients of clotting factor concentrates made before 1987
- Recipients of blood transfusions or solid organ transplants before July 1992
- Patients who have ever received long-term hemodialysis treatment
- Persons with known exposures to HCV, such as
  - Health care workers after needle sticks involving HCV-positive blood
  - Recipients of blood or organs from a donor who later tested HCV-positive
- All persons with HIV infection
- Children born to HCV-positive mothers. To avoid detecting maternal antibody, these children should be tested with HCV RNA after 2 months of age.

How is hepatitis C virus spread from one person to another?
Hepatitis C virus is spread primarily by direct contact with human blood, particularly through large or repeated percutaneous (i.e., passage through the skin) exposures to infectious blood, including:

- Injection drug use (currently the most common means of HCV transmission in the United States)
- Receipt of donated blood, blood products, and organs (once a common means of transmission, but now rare in the United States since blood screening became available in 1992)
- Needle stick injuries in health care settings
- Birth to an HCV-infected mother
HCV can also be spread infrequently through:
- Sex with an HCV-infected person (an inefficient means of transmission)
- Sharing personal items contaminated with infectious blood, such as razors or toothbrushes (also inefficient vectors of transmission)
- Other health care procedures that involve invasive procedures, such as injections (usually recognized in the context of outbreaks)
- Unregulated tattooing

Is there any evidence that hepatitis C virus has been spread during medical or dental procedures done in the United States?
Medical and dental procedures done in most settings in the United States do not pose a risk for the spread of hepatitis C. There have, however, been some reports that hepatitis C virus has been spread between patients in hemodialysis units where supplies or equipment may have been shared between patients and in outpatient clinics where proper infection control was not maintained. If health care-associated HCV infection is suspected, this should be reported to state and local public health authorities.

Can hepatitis C virus be spread by sexual activity?
Yes, but this does not occur very often. If you are having sex, but not with one steady partner:
- You and your partners can get other diseases spread by having sex (e.g. HIV, hepatitis B, syphilis, gonorrhea or chlamydia);
- You should use condoms correctly and every time you have sex; and
- You should be vaccinated against hepatitis B.

Can hepatitis C virus be spread within a household?
Yes, but this does not occur very often. If hepatitis C virus is spread within a household, it is most likely due to direct exposure to the blood of an infected household member.

How can you protect yourself from getting hepatitis C and other diseases spread by contact with human blood?
- Do not ever shoot drugs. If you shoot drugs, stop and get into a treatment program. If you cannot stop, never reuse or share syringes, water or drug works, and be vaccinated against hepatitis A and hepatitis B.
- Do not share toothbrushes, razors or other personal care articles. They might have blood on them.
- If you are a healthcare worker, always follow Standard Precautions and safely handle needles and other sharps. Get vaccinated against hepatitis B.
- Consider the health risks if you are thinking about getting a tattoo or body piercing. You can get infected if:
  - The tools that are used have someone else’s blood on them.
  - The artist or piercer doesn’t follow good health practices, such as washing hands and using disposable gloves.
  - The ink used for your tattoo is contaminated with someone else’s blood.

What can persons with hepatitis C virus infection do to protect their livers?
- Stop drinking alcohol.
- See the doctor regularly.
- Do not start any new medicines or use over-the-counter, herbal and other medicines or supplements without a physician’s knowledge.
- Get vaccinated against hepatitis A and hepatitis B.
What other information should patients with hepatitis C be aware of?

- Hepatitis C virus is not spread by sneezing, hugging, coughing, food, or water, sharing eating utensils or drinking glasses, or casual contact.
- Persons should not be excluded from work, school, play, child-care, or other settings because of their hepatitis C virus infection status. There is no evidence of hepatitis C transmission from food handlers, teachers, or other service providers in the absence of blood-to-blood contact. There is a low but present risk for transmission with sex partners.
- Sharing personal items that might have blood on them, such as toothbrushes or razors, can pose a risk to others.
- Cuts and sores on the skin should be covered to keep from spreading infectious blood or secretions.
- Donating blood, organs, tissue, or semen can spread hepatitis C to others.
- Involvement with a support group may help patients cope with hepatitis C.

What are the chances of persons with hepatitis C virus infection developing chronic HCV infection, chronic liver disease, cirrhosis, liver cancer, or dying because of hepatitis C?

Of every 100 persons infected with HCV, approximately:
- 75-85 persons will develop chronic HCV infection
- 60-70 persons will develop chronic liver disease
- 5-20 persons will develop cirrhosis over a period of 20 to 30 years
- 1-5 persons will die from the consequences of chronic infection (liver cancer or cirrhosis)

What is the treatment for chronic hepatitis C?

Because of advances in the field of antiviral therapy for chronic hepatitis C, individuals with hepatitis C should consult with physician specialists knowledgeable about hepatitis C to obtain the most up-to-date recommendations regarding treatment.

Can people become infected with a different strain of HCV after they have cleared the initial infection?

Yes. Prior infection with HCV does not protect against later infection with the same or different genotypes of the virus. This is because people infected with HCV typically have an ineffective immune response due to changes in the virus during infection. For the same reason, no effective pre- or post-exposure prophylaxis is available.
What is the risk for hepatitis C virus infection from a needle stick exposure to hepatitis C virus contaminated blood?
After needle stick or sharps exposure to HCV-positive blood, the risk of HCV infection is approximately 0.1%.

Other than needle sticks, do other exposures, such as splashes to the eye, pose a risk to healthcare personnel for hepatitis C transmission?
Although a few cases of hepatitis C transmission via blood splash to the eye have been reported, the risk for such transmission is expected to be very low. Avoiding occupational exposure to blood by following Standard Precautions is the primary way to prevent transmission of bloodborne infections among healthcare personnel. Depending on the medical procedure involved, Standard Precautions may include the appropriate use of personal protective equipment such as gloves, masks, gowns, and protective eyewear.

What is the recommended management of a health care worker with occupational exposure to HCV?
Postexposure prophylaxis (PEP) for hepatitis C is not recommended, as outlined in the 2001 MMWR on management of health-care personnel (HCP) who have occupational exposure to blood and other body fluids. Test the source for HCV RNA. If the source is HCV RNA positive, or the HCV infection status is unknown, follow this testing algorithm:

- Perform baseline testing for anti-HCV and ALT; AND
- Test with HCV RNA at four to six weeks after exposure (follow-up testing with anti-HCV can also be performed at four to six months)

Should hepatitis C virus-infected healthcare workers be restricted in their work?
There are no CDC recommendations to restrict a healthcare worker who is infected with hepatitis C virus. The risk of transmission from an infected healthcare worker to a patient appears to be very low. All healthcare personnel, including those who are hepatitis C virus-positive, should follow strict aseptic technique and Standard Precautions, including appropriate hand hygiene, use of protective barriers, and safe injection practices.